Samik Pharmaceutical headed straight to the upper limit, driven by foreigners' buying streak for five consecutive trading days.

Settles at 7,700 Won Upper Limit in Early Trading

On the 15th, in the KOSDAQ market, Samik Pharmaceutical is currently trading at 7,700 won as of the morning, up 1,770 won (29.85%) from the previous trading day. The stock rose to the price limit, entering the upper limit from early trading, and trading volume also increased significantly.

Foreign Supply-Demand Change + Expanded Interest in Pharma & Biotech

The surge is attributed to changes in foreign supply-demand and improved investor sentiment. Samik Pharmaceutical has continued its upward trend over the past few trading days, showing a gradual upward pattern, and with its intraday settlement at the upper limit today, assessments suggest that short-term momentum has strengthened.

The heightened interest in the pharmaceutical and biotech sectors overall also played a positive role. Recently, the stock market has seen a rotational buying trend with capital moving toward small- and mid-cap biotech and pharmaceutical stocks that highlight expectations for earnings improvement and growth potential.

"Volatility to Expand After Surge... Chasing Buys Should Be Cautious"

Market experts advise that for upper-limit stocks, the likelihood of expanded short-term volatility is high, requiring a cautious approach to chasing buys. In particular, they point out that profit-taking volume may emerge after a surge, making it necessary to simultaneously monitor trading volume and supply-demand trends.

Samik Pharmaceutical ranked among the top gainers on KOSDAQ today, and whether it will continue to rise is expected to depend on the sustainability of supply-demand and the maintenance of investor sentiment as key variables.

[This article includes content that received assistance from some AI tools during the information organization and sentence composition process, based on publicly available materials and market data. This article does not constitute a recommendation for any specific investment, and all decisions and responsibilities lie with the investor.]